Tazverik Accelerated Approval: Disease Rarity And Unmet Need Won Out Over Efficacy Concerns

 
• By Sue Sutter
  
Drug Review Profile regular column
US FDA exercised regulatory flexibility with the accelerated approval of Tazverik.

More from Drug Review Profiles

More from Product Reviews